Stock Track | Echo IQ Soars 5.88% Intraday on Pro Medicus Partnership and FDA Approval Catalyst

Stock Track

Jun 26

Echo IQ Ltd's stock surged 5.88% during intraday trading on Friday, driven by positive developments surrounding a key strategic partnership and regulatory progress.

The movement follows the announcement of a heads of agreement with Pro Medicus to establish a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million, with an additional A$10 million contingent upon U.S. Food and Drug Administration clearance of Echo IQ's EchoSolv heart-failure product. Analysts view this deal as a material endorsement from a global imaging technology leader, providing a timely boost to Echo IQ's cash position and significantly enhancing its immediate U.S. commercialization opportunity.

Analysts have responded positively to the news, with Petra Capital raising its price target on Echo IQ by 19% to A$1.30 per share and Ord Minnett increasing its target by 20% to A$1.80 per share. The FDA clearance is seen as a key catalyst, with parallels drawn to a previous successful investment by Pro Medicus in another ASX-listed company prior to its product receiving FDA approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1189392080"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189392080\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189392080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189392080","market":"sg","top_or_hot":-1,"title":"Stock Track | Echo IQ Soars 5.88% Intraday on Pro Medicus Partnership and FDA Approval Catalyst","media":"Stock Track","content":"<p>Echo IQ Ltd's stock surged 5.88% during intraday trading on Friday, driven by positive developments surrounding a key strategic partnership and regulatory progress.</p><p>The movement follows the announcement of a heads of agreement with Pro Medicus to establish a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million, with an additional A$10 million contingent upon U.S. Food and Drug Administration clearance of Echo IQ's EchoSolv heart-failure product. Analysts view this deal as a material endorsement from a global imaging technology leader, providing a timely boost to Echo IQ's cash position and significantly enhancing its immediate U.S. commercialization opportunity.</p><p>Analysts have responded positively to the news, with Petra Capital raising its price target on Echo IQ by 19% to A$1.30 per share and Ord Minnett increasing its target by 20% to A$1.80 per share. The FDA clearance is seen as a key catalyst, with parallels drawn to a previous successful investment by Pro Medicus in another ASX-listed company prior to its product receiving FDA approval.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Echo IQ Soars 5.88% Intraday on Pro Medicus Partnership and FDA Approval Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Echo IQ Soars 5.88% Intraday on Pro Medicus Partnership and FDA Approval Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-26 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Echo IQ Ltd's stock surged 5.88% during intraday trading on Friday, driven by positive developments surrounding a key strategic partnership and regulatory progress.</p><p>The movement follows the announcement of a heads of agreement with Pro Medicus to establish a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million, with an additional A$10 million contingent upon U.S. Food and Drug Administration clearance of Echo IQ's EchoSolv heart-failure product. Analysts view this deal as a material endorsement from a global imaging technology leader, providing a timely boost to Echo IQ's cash position and significantly enhancing its immediate U.S. commercialization opportunity.</p><p>Analysts have responded positively to the news, with Petra Capital raising its price target on Echo IQ by 19% to A$1.30 per share and Ord Minnett increasing its target by 20% to A$1.80 per share. The FDA clearance is seen as a key catalyst, with parallels drawn to a previous successful investment by Pro Medicus in another ASX-listed company prior to its product receiving FDA approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EIQ.AU","symbol_name":"ECHOIQ LTD","start_time":0,"source_url":"","article_id":"1189392080","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189392080","pubTimestamp":1782432878,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Echo IQ Ltd's stock surged 5.88% during intraday trading on Friday, driven by positive developments surrounding a key strategic partnership and regulatory progress.The movement follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EIQ.AU":"ECHOIQ LTD"},"translate_title":"个股追踪|Pro Medicus合作及FDA批准催化剂Echo IQ盘中大涨5.88%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EIQ.AU":1},"content_text":"Echo IQ Ltd's stock surged 5.88% during intraday trading on Friday, driven by positive developments surrounding a key strategic partnership and regulatory progress.The movement follows the announcement of a heads of agreement with Pro Medicus to establish a strategic investment and U.S. commercial partnership. Pro Medicus will invest an initial A$10 million, with an additional A$10 million contingent upon U.S. Food and Drug Administration clearance of Echo IQ's EchoSolv heart-failure product. Analysts view this deal as a material endorsement from a global imaging technology leader, providing a timely boost to Echo IQ's cash position and significantly enhancing its immediate U.S. commercialization opportunity.Analysts have responded positively to the news, with Petra Capital raising its price target on Echo IQ by 19% to A$1.30 per share and Ord Minnett increasing its target by 20% to A$1.80 per share. The FDA clearance is seen as a key catalyst, with parallels drawn to a previous successful investment by Pro Medicus in another ASX-listed company prior to its product receiving FDA approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}